Third, this study evaluated only the effect of different CYP2C19 genotypes on the clinical efficacy of ticagrelor-aspirin compared with clopidogrel-aspirin among patients receiving the drugs after stroke or TIA. Here, CYP2C19 is linked to transient ischemic attack.